Cargando…
Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
BACKGROUND: Sacubitril/valsartan has been incorporated into guidelines based on the results of the PARADIGM-HF trial, which demonstrated reduced mortality in stable patients with heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan is recommended in addition to other HF therapi...
Autores principales: | Peppin, Katie L., Tellor, Katie B., Armbruster, Anastasia L., Schwarze, Martin W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034425/ https://www.ncbi.nlm.nih.gov/pubmed/32128057 http://dx.doi.org/10.1080/20009666.2019.1708638 |
Ejemplares similares
-
Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018) -
Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12 months: a retrospective study
por: Muzzey, Mikayla, et al.
Publicado: (2020) -
Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021) -
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
por: Khan, Muhammad Nauman, et al.
Publicado: (2023) -
Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
por: López‐Azor, Juan Carlos, et al.
Publicado: (2019)